Elobixibat and its potential role in chronic idiopathic constipation.
Level 5 - mechanism / opinion, no new human data
Narrative review of pharmacological mechanisms with no primary human trial data presented in the abstract.
PubMed 25057297 · doi:10.1177/1756283X14528269
What was done
This narrative review synthesized the role of bile acids, the enterohepatic circulation, and the ileal bile acid transporter inhibitor elobixibat (A3309) in the management of chronic idiopathic constipation.
What was found
No numerical trial data, effect estimates, or statistical findings are reported in the abstract. The review describes the mechanism whereby elobixibat inhibits ileal bile acid absorption, thereby increasing delivery of bile acids to the colon to exert osmotic and pro-motility effects. Secondary reported effects include reduced farnesoid X receptor activation, lower fibroblast growth factor-19 secretion into the portal circulation, and increased bile acid synthesis.
Why it matters
It outlines a distinct mechanistic class of therapy that utilizes the body's endogenous bile acids to treat chronic constipation.
Limits
The abstract contains no primary quantitative clinical efficacy data, safety metrics, comparator arms, or sample sizes, and does not report a systematic review methodology.
Cited by
- supports A deficiency of concentrated bile salts entering the small intestine promotes constipation, as bile salts assist digestion and prevent constipation.
- context Bile acts to lubricate the colon to maintain normal bowel transit.